Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty patients (33 male, 7 female) with refractory epilepsy were randomized to receive ascending weekly doses of adjunctive remacemide hydrochloride in a b.i.d. or q.i.d. regimen, or placebo for up to 1 month. Assessments included routine physical examination and laboratory tests, recording of adverse events and seizure frequency, and neuropsychological tests. Trough plasma concentrations of concomitant AEDs were measured at weekly intervals. Trough plasma concentrations of remacemide and its desglycinyl metabolite were measured before each dose increment, and complete 24-hour profiles were measured at steady state following administration of 600 mg day(-1)and 1200 mg day(-1). A daily dose of 1200 mg was well tolerated in a q.i.d. regimen and up to 800 mg was well tolerated in a b.i.d. regimen. The most common adverse events were dizziness, diplopia, dyspepsia and abdominal pain. On some occasions, these were considered to be related to raised concentrations of concomitant AEDs. No adverse effects were observed on seizure frequency. Neuropsychology tests revealed no significant changes. Remacemide and the desglycinyl metabolite demonstrated dose proportional pharmacokinetics over the dose range tested.
 ...
PMID:Remacemide hydrochloride: a placebo-controlled, one month, double-blind assessment of its safety, tolerability and pharmacokinetics as adjunctive therapy in patients with epilepsy. 1116 51

Thirty patients with different forms of epilepsy were treated with toreal in dosage 200 mg per day. The clinical efficacy was assessed after 8 and 12 weeks. Side-effects and changes of laboratory parameters were assessed taking into account their intensity, duration and possible relation to the drug. Toreal was most effective in symptomatic local forms of epilepsy (76-95%) and less effective in idiopathic forms (up to 70%). In the period of dose titration, higher fatigue (70%), sleepiness (53.33%) were recorded more often than dizziness, paresthesias, dry mouth, diplopia, dyspepsia, ataxia and others side-effects. Higher fatigue remained in 70% of patients to the end of 12th week while the frequency of other side- effects has decreased. Overall, the severity of side-effects was mild that did not lead to changing of dose or drug's withdrawal.
 ...
PMID:[The use of toreal in the monotherapy of epilepsy in adults]. 1936 70